TABLE 5.
Association between selected characteristics and immune response in patients with MD
| Category | Univariate analysis | Multivariate analysis b | ||
|---|---|---|---|---|
| RR (95% CI) | P value | RR (95% CI) | P value | |
| Male (vs female) | 0.77 (0.38‐1.56) | .463 | ‐‐‐ | ‐‐‐ |
| Age (increase by 1 year) | 0.96 (0.94‐0.99) | .005 | 0.97 (0.95‐0.99) | .004 |
| Weight (increase by 1 kg) | 0.95 (0.91‐0.98) | .007 | ‐‐‐ | ‐‐‐ |
| DM1 (vs other MDs) | 0.35 (0.15‐0.78) | .012 | 0.42 (0.21‐0.85) | .017 |
| Bedridden (vs others a ) | 0.32 (0.14‐0.72) | .007 | 0.27 (0.14‐0.51) | <.001 |
| TPPV (vs NPPV or none) | 1.31 (0.59‐2.93) | .499 | ‐‐‐ | ‐‐‐ |
| Underlying disease | ||||
| Heart failure | 1.73 (0.79‐3.78) | .163 | ‐‐‐ | ‐‐‐ |
| Diabetes mellitus | 0.15 (0.01‐3.90) | .249 | ‐‐‐ | ‐‐‐ |
| Allergic disease | 0.20 (0.01‐3.03) | .241 | ‐‐‐ | ‐‐‐ |
|
Side effect of COVID‐19 vaccine (any vs none) | ||||
| After first dose | 1.62 (0.70‐3.75) | .255 | ‐‐‐ | ‐‐‐ |
| After second dose | 1.38 (0.62‐3.04) | .422 | ‐‐‐ | ‐‐‐ |
| After either of the two doses | 1.13 (0.55‐2.31) | .740 | ‐‐‐ | ‐‐‐ |
Abbreviations: CI, confidence interval; MD, muscular dystrophy; NPPV, noninvasive positive pressure ventilation; RR, relative ratio; TPPV, tracheostomy positive pressure ventilation.
a
Others: wheelchair user or ambulatory.
b
Adjusted for age, type of MD, and ambulatory status.